1992
Kevin W. Sharer named president and chief operating officer

1993
Regulators in Australia, Canada and Europe approve NEUPOGEN® for the treatment of severe chronic neutropenia

Amgen receives Australian, Canadian, European Community and U.S. regulatory approval for its multi-product manufacturing facility in Thousand Oaks

1994
FDA approves NEUPOGEN® for patients undergoing bone marrow transplantation and for patients with severe chronic neutropenia

Amgen opens subsidiary in Japan, Amgen K.K.

Amgen receives U.S. Department of Commerce National Medal of Technology, the nation's highest honor for innovation

Amgen acquires Synergen, Inc., a biotechnology company based in Boulder, Colorado

1995
FDA approves NEUPOGEN® for use in peripheral blood progenitor cell (PBPC) transplants

1996
Regulators in Australia and Canada approve NEUPOGEN® for use in PBPC transplants

1997
FDA approves INFERGEN® for treating patients with Hepatitis C (Today, INFERGEN® is marketed by Yamanouchi Pharmaceutical Co., Ltd. in Japan and by InterMune, Inc. in the U.S.)

1998
FDA approves NEUPOGEN® for use in support of treatment of acute myeloid leukemia

FDA approves Immunex's ENBREL® to treat patients with moderately to severely active rheumatoid arthritis